ID   C99
AC   CVCL_8176
DR   cancercelllines; CVCL_8176
DR   CancerTools; 151761
DR   Cell_Model_Passport; SIDM01547
DR   ColonAtlas; C99
DR   Cosmic; 948840
DR   Cosmic; 986012
DR   Cosmic; 995381
DR   Cosmic; 1043804
DR   Cosmic; 1312296
DR   Cosmic; 2301963
DR   Cosmic; 2800566
DR   DepMap; ACH-001461
DR   ECACC; 12022905
DR   GEO; GSM1346865
DR   GEO; GSM1374425
DR   GEO; GSM1448204
DR   GEO; GSM3145697
DR   IARC_TP53; 21765
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   Wikidata; Q54808275
DR   Ximbio; 151761
RX   PubMed=10051639;
RX   PubMed=10737795;
RX   PubMed=16418264;
RX   PubMed=18258742;
RX   PubMed=20606684;
RX   PubMed=23272949;
RX   PubMed=24755471;
RX   PubMed=25926053;
RX   PubMed=29101300;
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Microsatellite instability: Stable (MSS) (PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16418264).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Rectum; UBERON=UBERON_0001052.
ST   Source(s): DepMap; ECACC; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,14
ST   D16S539: 11,13
ST   D18S51: 12
ST   D21S11: 28,30
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   D8S1179: 11,13
ST   FGA: 27
ST   Penta D: 13
ST   Penta E: 10,12
ST   TH01: 8,9.3
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C9383; Rectal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   69Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=10051639; DOI=10.1073/pnas.96.5.2316;
RA   Efstathiou J.A., Liu D., Wheeler J.M., Kim H.C., Beck N.E., Ilyas M.,
RA   Karayiannakis A.J., Mortensen N.J., Kmiot W., Playford R.J.,
RA   Pignatelli M., Bodmer W.F.;
RT   "Mutated epithelial cadherin is associated with increased
RT   tumorigenicity and loss of adhesion and of responsiveness to the
RT   motogenic trefoil factor 2 in colon carcinoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2316-2321(1999).
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//